Leaderboards/HER2/EGFR in Cancer Research

HER2/EGFR in Cancer Research

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
James Cregg
Revolution Medicines (United States)
2
Mythili Shastry
Sarah Cannon Research Institute
3
Ximena Baez‐Navarro
Erasmus MC
4
Hsuan‐Ping Chang
University at Buffalo, State University of New York
5
Sofía Llorente
Vall d'Hebron Hospital Universitari
6
Tomohiro Watanabe
Ajinomoto (United States)
7
Nanae Horisawa
Nagoya City University
8
Louise Conilh
Eli Lilly (United States)
9
Alexis Q. Dean
Center for Drug Evaluation and Research
10
Toby Journeaux
University of Cambridge

Papers

1
Publication in Journal of Medicinal Chemistry (2025) [72 citations, W4408247136]
Journal of Medicinal Chemistry|2025
72 cit.
2
Publication in Nature Chemistry (2024) [53 citations, W4397010478]
Nature Chemistry|2024
53 cit.
3
Publication in Journal of Medicinal Chemistry (2024) [53 citations, W4403472054]
Journal of Medicinal Chemistry|2024
53 cit.
4
Publication in Journal of Medicinal Chemistry (2025) [40 citations, W4407898113]
Journal of Medicinal Chemistry|2025
40 cit.
5
HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
Pathology|2024
20 cit.
6
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Breast Cancer Research|2024
17 cit.
7
Publication in Journal of Pharmacokinetics and Pharmacodynamics (2025) [11 citations, W4410080091]
Journal of Pharmacokinetics and Pharmacodynamics|2025
11 cit.
8
Publication in Angewandte Chemie International Edition (2024) [10 citations, W4403537168]
Angewandte Chemie International Edition|2024
10 cit.
9
Publication in British Journal of Clinical Pharmacology (2024) [9 citations, W4393866715]
British Journal of Clinical Pharmacology|2024
9 cit.
10
A Comparison Between Immunohistochemistry and mRNA Expression to Identify Human Epidermal Growth Factor Receptor 2–Low Breast Cancer
Archives of Pathology & Laboratory Medicine|2024
6 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
E.P. Winer
Dana-Farber Cancer Institute
2
Erika Hamilton
Sarah Cannon
3
Kevin Kalinsky
Emory University
4
Mahmoud Charif
University of Cincinnati Medical Center
5
Julia A. Beaver
Center for Drug Evaluation and Research
6
Chanchal Goswami
AMRI Hospitals
7
Patrick Schneier
Unknown
8
Maria Vittoria Dieci
Istituto Oncologico Veneto
9
Hirohito Yamaguchi
China Medical University
10
Lisanne Renskers
Netherlands Heart Registration

Papers

1
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
Journal of Clinical Oncology|2023
191 cit.
2
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors
Clinical Cancer Research|2022
171 cit.
3
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
The Breast|2022
133 cit.
4
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Nature Medicine|2024
128 cit.
5
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
npj Breast Cancer|2022
103 cit.
6
Rise of Antibody-Drug Conjugates: The Present and Future
American Society of Clinical Oncology Educational Book|2023
102 cit.
7
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
npj Breast Cancer|2022
97 cit.
8
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
New England Journal of Medicine|2025
94 cit.
9
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
Future Oncology|2024
91 cit.
10
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
JAMA Oncology|2022
80 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Pasi A. Jänne
Harvard University
2
William McGuire
University of York
3
Daniel F. Hayes
University of Michigan–Ann Arbor
4
Larry Norton
Memorial Sloan Kettering Cancer Center
5
Dennis J. Slamon
University of California, Los Angeles
6
Matthew Meyerson
Broad Institute
7
Norman Wolmark
NSABP Foundation
8
Michael F. Press
USC Norris Comprehensive Cancer Center
9
Bruce E. Johnson
Harvard University
10
William R. Sellers
Broad Institute

Papers

1
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
Science|1987
11.7k cit.
2
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine|2001
11.5k cit.
3
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science|2004
9.4k cit.
4
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Science|1989
6.9k cit.
5
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
New England Journal of Medicine|2004
6.4k cit.
6
Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer
New England Journal of Medicine|2002
6.2k cit.
7
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine|2005
5.4k cit.
8
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
New England Journal of Medicine|2004
4.6k cit.
9
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Journal of Clinical Oncology|2006
4.5k cit.
10
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Science|2007
4.5k cit.

Reagents for HER2/EGFR in Cancer Research

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

Cell Signaling Technology

ZHX2 Antibody

Cited in 12 papers
#20937$317
View Evidence →

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 63

Androgen Receptor (D6F11) Rabbit Monoclonal Antibody (Alexa Fluor® 594 Conjugate)

Cited in 21 papers
#8938$465
View Evidence →
Cell Signaling TechnologyEvidence 64

DOG1/Anoctamin 1 (D1M9Q) Rabbit Monoclonal Antibody

Cited in 18 papers
#14476$160,354
View Evidence →
Cell Signaling TechnologyEvidence 68

HER3/ErbB3 (D22C5) Rabbit Monoclonal Antibody

Cited in 18 papers
#12708$1,811,015
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

c-erbB-2, c-neu

Cited in 45 papers
#A0485
View Evidence →
Cell Signaling TechnologyEvidence 65

Phospho-Rb (Ser807/811) (D20B12) Rabbit Monoclonal Antibody (Pacific Blue™ Conjugate)

Cited in 23 papers
#75864$493
View Evidence →
Cell Signaling TechnologyEvidence 66

Rb (4H1) Mouse Monoclonal Antibody (BSA and Azide Free)

Cited in 21 papers
#61121$865
View Evidence →